SCHEMBL7680485

SCHEMBL7680485

CC(C)(C)OC(=O)N1CCc2ncn(C(=O)OC(C)(C)C)c2C1c1ccc(C#N)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.43
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
EGLN2 Q96KS0 1/20 0.36
EED O75530 1/20 0.36
RBBP4 Q09028 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36
AEBP2 Q6ZN18 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TRPA1 O75762 1/20 0.35
AR P10275 3/20 0.35
TPH1 P17752 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7680493 0.95 GPR119 (0.42) GPR119KDM4EMEN1ALDH1A1MAPT
SCHEMBL17151155 0.74 GPR119 (0.50) GPR119NR1H2NR1H3EEDRBBP4
SCHEMBL30979323 0.71 GPR119 (0.46) GPR119NR1H2NR1H3EGLN2EED
SCHEMBL4168333 0.70 GPR119 (0.61) GPR119KDM4EMAPTFASN
SCHEMBL24877558 0.70 GPR119 (0.52) GPR119EGLN2JAK2JAK1TRPA1
SCHEMBL18357570 0.68 GPR119 (0.48) GPR119EGLN2JAK2JAK1TRPA1
SCHEMBL15109942 0.67 GPR119 (0.49) GPR119MEN1ALDH1A1MAPTKMT2A
SCHEMBL31569208 0.66 GPR119 (0.41) GPR119KDM4EMEN1ALDH1A1MAPT
SCHEMBL8151274 0.64 RORC (0.39) KMT2ANR1H2NR1H3
SCHEMBL6269762 0.64 GPR119 (0.57) GPR119ALDH1A1MAPTNR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037888-A1 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease MERCK & CO., INC. 2002-03-28 US disclosed
US-6284755-B1 Inhibitors of prenyl-protein transferase MERCK & CO., INC. 2001-09-04 US disclosed
WO-2000034437-A2 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037888-A1 4-imidazol-1-ylmethyl-2-(2-(2-oxo-piperidin-1-yl)-phenoxy) -benzonitrile for example; farnesyl-protein transferase inhibitors; treating cancer, benign proliferative disorder, hepatitis virus, restenosis, and polycystic kidney disease FNTA, PKD1, FNTB GPR119 3264/4885KDM4E 1518/4885MEN1 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.